For individuals with symptomatic disease demanding therapy, ibrutinib is commonly encouraged based on four stage III randomized clinical trials comparing ibrutinib with chlorambucil monotherapy106 together with other usually employed CIT mixtures, particularly FCR, bendamustine additionally rituximab and chlorambucil additionally obinutuzumab (ClbO